Kardigan, Inc. KARD
Kardigan, Inc. (Nasdaq: KARD) is a cardio-renal-metabolic drug developer. Its lead program, Danicamtiv, is in Phase 3 for Genetic dilated cardiomyopathy (MYH7 and TTN variants). Its next catalyst on record is ataciguat: Kardigan expects topline data from Phase 2b KATALYST-AV trial in second half of 2027. (H2 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ataciguat — Kardigan expects topline data from Phase 2b KATALYST-AV trial in second half of 2027. (H2 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Danicamtiv (KINSHIP-DCM Phase 2b/3) | Genetic dilated cardiomyopathy | small molecule | Phase 3 |
| Ataciguat (KATALYST-AV Phase 2b) | Moderate calcific aortic valve stenosis | small molecule | Phase 2 |
| Tonlamarsen (KARDINAL-ASH Phase 2) | Acute severe hypertension post-hospitalization | RNA (siRNA/ASO/mRNA) | Phase 2 |
Recent results and decisions
- Nov 6, 2026completed enrollment Kardigan completes enrollment in Phase 2b KATALYST-AV trial of ataciguat in aortic stenosis.
Completing enrollment in KATALYST-AV is a foundational milestone for our program and an important one for people with aortic stenosis.
Filing - Aug 11, 2026completed enrollment Completed enrollment of Cohort 1 of Phase 2b KINSHIP-DCM in July 2026.
In July, the Company completed enrollment of Cohort 1 (myosin heavy chain 7, or MYH7, and titin, or TTN, patients) of the Phase 2b KINSHIP-DCM clinical trial and enrollment of the Phase 3 portion is now underway.
Filing - Aug 11, 2026started Randomized first patient in Phase 2 KARDINAL-ASH in Q2 2026.
In the second quarter, the Company randomized the first patient in KARDINAL-ASH and expects to share Phase 2 topline data in the first half of 2027.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.